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Abstract
The recent COVID-19 outbreak caused by SARS-CoV-2 virus has sparked a new spectrum of investigations, research
and studies in multifarious directions. Efforts are being made around the world for discovery of effective vaccines/drugs
against COVID-19. In this context, Ayurveda, an alternative traditional system of medicine in India may work as an
adjuvant therapy in compromised patients. We selected 40 herbal leads on the basis of their traditional applications. The
phytomolecules from these leads were further screened through in-silico molecular docking against two main targets of
SARS-CoV-2 i.e. the spike protein (S; structural protein) and the main protease (MPRO; non-structural protein). Out of the
selected 40, 12 phytomolecules were able to block or stabilize the major functional sites of the main protease and spike
protein. Among these, Ginsenoside, Glycyrrhizic acid, Hespiridin and Tribulosin exhibited high binding energy with
both main protease and spike protein. Etoposide showed good binding energy only with Spike protein and Teniposide
had high binding energy only with main protease. The above phytocompounds showed promising binding efﬁciency
with target proteins indicating their possible applications against SARS-CoV-2. However, these ﬁndings need to be
validated through in vitro and in vivo experiments with above mentioned potential molecules as candidate drugs for the
management of COVID-19. In addition, there is an opportunity for the development of formulations through different
permutations and combinations of these phytomolecules to harness their synergistic potential.
Keywords: Ayurveda, COVID-19, Main protease, SARS-CoV-2, Spike-RBD protein

1. Introduction

T

he human coronavirus (CoV) is an enveloped,
single stranded positive sense RNA virus of
Coronaviridae family and Nidovirales order which is
usually responsible for upper respiratory and digestive tract infections in humans [1]. Earlier, the Severe
Acute Respiratory Syndrome-CoV (SARS-CoV) in
2002 and Middle East Respiratory Syndrome-CoV
(MERS-CoV) in 2013 spread in several countries
causing severe illnesses like pneumonia, bronchiolitis, meningitis etc. However, in the present scenario
the fatality rate due to SARS-CoV-2 is ~2e3% [2,3]. It is
believed that initially SARS-CoV-2 virus had spilled

over from animal reservoir to humans via an intermediate host and aggressively infected the humans
with increased severity and then by human to human
transmission leading to pandemic via global travel, as
declared by the WHO on 11th March, 2020. The
symptoms in COVID-19 patients typically resemble
those of the SARS, which include dry cough, high
fever and at later stages difﬁculty in breathing due to
lower respiratory tract infection. The genome of CoV2 (~30 kb) encodes four major structural proteins:
Spike (S), Membrane (M), Envelope (E) and Nucleocapsid (N). Spike protein facilitates entry into the
target cell with its short intracellular tail, transmembrane anchor, large ectodomain with receptor
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binding (S-1) and membrane-fusing (S-2) subunits.
Sequence of SARS-CoV-2 has 79.5% similarity with
SARS-CoV. Receptor binding domain/motif (RBM) in
Spike protein is conserved between CoV-1 and CoV-2,
suggesting that Coronaviruses use the same Angiotensin-Converting Enzyme-2 (ACE2) receptor for
entry to the host's receptors in alveolar epithelial cells
of lungs [1].
Till date there is no effective remedy available for
this virus and the current line of treatment includes
use of combination of some antiviral agents and
broad-spectrum antibiotics. Several inhibitors of
HIV protease have been claimed to be efﬁcacious
against COVID-19; however, their results remain
unclear in animal models [4]. Remdesivir has been
found effective against SARS-CoV-2 both in vitro
and in vivo [5]. The Indian Council of Medical
Research (ICMR) has also recommended the use of
Hydroxychloroquine (400 mg dose) for the treatment of conﬁrmed or suspected COVID-19 patients
[6]. The use of plasma therapy as an alternative line
of treatment has been permitted in several countries
but its safety and efﬁcacy are under investigation [7].
Currently the management/treatment of COVID-19
has become quintessential and it is urgent to ﬁnd
out potential molecules either through modern
medicine or from traditional systems of medicine to
control the acuteness and casualities caused by
COVID-19 infection.
As per Ayurveda, infectious diseases can be
controlled by supporting the natural defense
mechanisms and boosting the immune system of
body that will be beneﬁcial for eradication of the
symptoms [8]. The concepts of epidemics and pandemics were known even at the time of Ayurveda as
Janapadodhwans, which occur due to variations in
Vayu, Jala, Desh and Kala [9]. One of the noted
Ayurvedacharya of ancient India, Sushurut had
classiﬁed eight different modes of communicable
diseases in his book Sushurut Samhita [10]. It has
been suggested that the aupsargika roga (communicable diseases) can be contained by practicing some
physical precautions and taking some protective
measures such as “Dhupana” (fumigation) with
“Rakshoghna Dravyas” (antimicrobial agents).
Thus, an integrative Ayurvedic approach using
poly-herbal combinations with medicinal plants
having anti-inﬂammatory, immunity boosting, antiasthmatic and anti-pneumonia activities with furin
like- proprotein convertase enzyme inhibitor might
help to combat COVID-19. The trimeric transmembrane spike (S) glycoprotein of coronavirus is
essential for the entry of virus into the cell via
attachment, fusion and penetration. After attachment, the S glycoprotein must be cleaved by host

cell proteases to enable the exposure of fusion sequences for entry into the cell. As furin proteases
are abundant in the human respiratory tract, it is
possible that S-glycoproteins of SARS-CoV-2 is
cleaved when it exits from epithelial cells and
consequently infect other cells efﬁciently. Thus to
inhibit the viral propagation, use of plant-based
furin-like convertase inhibitors will be a key
approach. However, systematic inhibition of furin
like enzymes may result in toxicity due to its use in
other cellular processes of human. So, the delivery
of small molecules of plant origin can provide local
relief against COVID-19. One most promising
example is diterpenes and succinoyl esters of
Andrographis paniculata, which exhibit prohormone/
proprotein convertase (PC) inhibitory properties
[11]. The ﬂavonoids isolated from Oroxylum indicum
were tested for inhibition of PC-enzymes including
furin using in vivo ﬂuorogenic peptide as substrate.
The study interprets that “these ﬂavonoids also
efﬁciently blocked the PC4-mediated processing of a
ﬂuorogenic peptide derived from the processing site
of its substrate, pro-Insulin Growth Factor-1
(proIGF-1)” and can have anticancer and antiviral
activities [12]. In another study, chloroform soluble
extract of Morus alba fruits, selected by proprotein
convertase subtilisin-kexin type 9 (PCSK9) mRNA
expression monitoring assay in HepG2 cells, led to
the isolation of a new benzofuran isomoracin D and
a naturally occurring N-(N-benzoyl-L-phenylalanyl)-L-phenylalanol along with 13 known compounds. Out of those, moracin C was found to
inhibit PCSK9 mRNA expression with an IC50 of
16.8 mM in HepG2 cells [13]. Besides this, various insilico studies have been conducted on some compounds of natural origin like polyphenols, tannins,
and polyacylated anthocyanins, exhibiting promising efﬁcacy against SARS-CoV-2 [14e17].
The phytomolecules obtained from plants possess
a wide spectrum of antimicrobial activity including
potent antiviral activities against diverse groups of
viruses [18]. This property of the plant extracts is
due to the presence of a large number of phytoconstituents belonging to diverse groups such as
phenols, ﬂavonoids, alkaloids, saponins, terpenoids,
glycosides, peptides etc. [15,19] with different modes
of action in inhibiting the growth of viruses. The
common mechanisms of actions include inactivation
of viral particles [20], inhibition of viral adsorption
and penetration [21] or entry, transcription [22], and
viral protein synthesis [23]. The phenols or phenolic
acids are important classes of phytomolecules displaying antiviral activity and the degree of activity
depends on its number of hydroxyl groups [15,24].
Flavonoids obtained from ethanolic extract of Ficus
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benjamina leaves were able to inhibit different
strains of Herpes Simplex Virus (HSV) infection
[25]. Berberine, a very potent member of protoberberine group of alkaloids inhibits HSV to enter
into the host cells [26] while indole alkaloid harmelin inhibits HSV-1 and HSV-2 infection in mice
by inhibiting immediate early transcription [27,28].
Apart from this, several plants have immunity
boosting or immunomodulatory effects rendered by
inducing the production of cytokines, interferons
and interleukins [29,30]. Artemisia annua, a wellknown anti-malarial plant is also reported to
possess anti-viral potential against a number of viruses [31]. Although plants have immense potential
for providing solutions to several emerging challenges and they can also have an important role as
an adjuvant therapy in management of diseases
until proper treatment is available. In order to select
effective phytocompounds against COVID-19, in the
present study, a number of herbal leads were
selected on the basis of their traditional applications. The phytomolecules from these leads were
further screened through in-silico molecular docking, against two major targets- the spike protein (S;
structural protein) and the main protease (MPRO;
non-structural protein) of the SARS-CoV-2.

phytomolecules were further evaluated against
human by using admetSAR prediction tool (http://
lmmd.ecust.edu.cn/admetsar2/). To predict the
essential pharmacokinetic nature of phytomolecules, properties such as absorption, permeability,
distribution, metabolism, mechanism, excretion and
toxicity were conducted to access their impact on
the targets of human body along with safety assessments (Table S1).

2. Material and methods

2.4. Molecular docking of phytocompounds with
selected SARS-CoV-2 targets

2.1. Screening and identiﬁcation of phytomolecules
It is crucial to recognize the most effective therapeutic and functional herbal leads for the cure and
prevention of SARS-CoV-2. Therefore, literature
mining was performed and a number of plants and
their phytomolecules (ligands) were selected from
ancient Ayurvedic scriptures and Samhitas as well as
recent scientiﬁc publications on the basis of their
therapeutic applications. The protein structures of
phytomolecules were retrieved from PubChem
database (https://pubchem.ncbi.nlm.nih.gov/) and
DrugBank (https://drugbank.ca/) for further analysis. Moreover, Remdesivir and Hydroxychloroquine were considered as standard ligands.
2.2. Characterization of selected phytomolecules
The selected phytomolecules (ligands) were
further characterized on the basis of their applications, record of uses against respiratory disorders
including SARS like symptoms, antiviral potential,
their absorbance in the human body, half-life,
toxicity, sustainability in humans with recommended dose and nature of solubility. Moreover,
the most promising pharmacologically active

2.3. Screening of SARS-CoV-2 targets
As per the previous studies, several targets
including spike glycoprotein, papain like protease
(PLpro), and main protease (Mpro) like 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp) were screened by
computational approach to design the effective
drugs against SARS-CoV-2 [32]. Out of different
targets, main protease (Mpro) was selected for molecular docking as it performs a decisive role in the
processing of polyproteins that are translated from
the viral mRNA [16,33]. Apart from that, Spike (S)
protein was also selected to further validate the
binding afﬁnity of screened phytomolecules with
other targets.

To unravel the infallible curation efﬁcacy against
SARS-CoV-2, the screening of potential ligands
have become a prime priority in current scenario.
After the selection it remains important to recognize
the binding efﬁnity of potent phytomolecules at
SARS-CoV-2 targets.
To ﬁnd out this, the selected ligands were
employed against the spike protein (structural protein) and main protease (non-structural protein) of
SARS-CoV-2, with their corresponding structure in
RCSB-PDB. These ligands were evaluated on the
basis of two methods. Firstly, the structures were
examined by using induced-ﬁt docking to evaluate/
analyze their active site blocking potential at structural level. The protein structures of SARS-CoV-2
main protease and spike-RBD with main protease
were downloaded from RCSB-PDB database
(https://www.rcsb.org/) using the ID, 6LU7, and
6LZG, respectively. These structures were further
optimized in SPDBv tool (https://spdbv.vital-it.ch/)
for gap and charge ﬁlling. A number of ligands were
downloaded from PubChem and DrugBank databases to check against selected receptors proteins.
The downloaded ligand structures were converted
from SDF (structure data ﬁle) to PDB (protein data
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bank) format using openbabel tool (http://www.
cheminfo.org/Chemistry/Cheminformatics/
FormatConverter/index.html).
The molecular interaction between protein and
ligand were checked using two molecular docking
methods. In the ﬁrst step, the ligands were screened
against receptor using autodock vina program
(http://vina.scripps.edu/), ligands with higher dG
were further selected for the induced-ﬁt docking
method based on the structural ﬁt using Hex
docking tool (http://hex.loria.fr/).
2.5. Ligand activity analysis
To reﬁne the docking results and explore the
interaction of ligand receptors with targeted site of
SARS-CoV-2, the interactions of hydrogen bonds and
hydrophobic contacts with residues of ligands were
analyzed through schematic diagrams of proteinligand interactions by using LIGPLOT v.4.5.3 [34].
Hydrogen bonds are indicated by dashed lines between the atoms involved, while hydrophobic contacts are represented by an arc with spokes radiating
towards the ligand atoms they contact. The contacted
atoms are shown with spokes radiating back.

3. Results
3.1. Screening of phytomolecules
Forty phytomolecules (ligands) were selected for
the identiﬁcation of potential candidates for higher
binding/blocking afﬁnity to suppress SARS-CoV-2.
Out of these, 12 phytomolecules were screened on
the basis of their bio-availability and therapeutic
applications. The selected phytomolecules (Table 1)
were reported as the major ingredients of different
medicinal plants native to India and are easily
available in the local markets in the respective
phyto-geographical regions.
3.2. Characterization of selected ligands
The selected ligands were further characterized
on the basis of their applications/record of uses
against respiratory disorders including SARS-like
symptoms, antiviral potential, absorbance in the
human body, half-life, toxicity, sustainability in
humans with recommended dose and nature of
solubility (Table 1). The phytomolecules were reported earlier as non-toxic and recommended for
human consumption. The biological half-life of the
selected phytomolecules ranged from 16 min to 7
days which further explains the efﬁcacy and digestion of the formulated drug after consumption in

dose dependent manner. Besides, the selected ligands also possessed antimicrobial activity against
several human pathogens along with adjuvant
beneﬁciary effects (Table 1).
3.3. Screening of SARS-CoV-2 targets
The main protease (Mpro) of SARS-CoV-2 was
selected as target for molecular docking against this
lethal virus responsible for COVID-19 respiratory
illness. Out of its four structural proteins viz., spike
(S), envelope (E), membrane (M) and nucleocapsid
(N), the S, E and M proteins jointly participate in
creating and maintaining the viral envelope. Apart
from these, many other non-structural proteins
(nsps) have also been identiﬁed in this virus [35],
main protease being the most functionally important non-structural protein. The main protease
processes the long polyprotein chain and proteolytically cleaves them, resulting in release of many
other nsps, which also contribute to viral replication
and other important functional processes [36]. This
makes main protease an attractive target against
SARS-CoV-2. The binding afﬁnity of screened
phytomolecules with spike protein of SARS-CoV-2
was also evaluated to analyze the binding afﬁnity of
selected ligands against structural protein.
3.4. Molecular docking of phytocompounds with
selected SARS-CoV-2 targets
Remdesivir and Hydroxychloroquine were taken
as standard ligand for comparison of both electrostatic potential as well as structural ﬁt. The selected
phytomolecules were evaluated against the binding
afﬁnity of standards. Out of 40 phytomolecules, 12
ligands viz., ginenoside, glycyrrhizic acid, etoposide,
rutin, podophyllotoxin, colchicine, hesperidin,
ampelopsin, meliacarpin, berberine, teniposide and
tribulosin were found promising against main protease and spike protein of SARS-CoV-2 (Table 2 and
Table 3). Among these 12 promising ligands, nine
showed higher blocking potential against main
protease (Fig. 1) and spike protein (Fig. S1).
Hydroxychloroquine showed binding energy
value (dG) of 537.1 and 225.9 in induced-ﬁt
method while electrostatic docking yielded 5.6 and
5.8 with main protease protein and spike protein
respectively. The corresponding values in respect of
Remdesivir following induced-ﬁt method were
731.38 and 621.6 with main protease and spike
protein, respectively. The values obtained following
electrostatic docking were 9.4 and 7.4, with main
protease and spike protein, respectively. The ligands
were selected for further analysis on the basis of

Anti-cancer Rh2 [74]; HIV protease inhibitor [75]; Antiherpes virus [76]; protective effects against DOX-induced
cardiotoxicity [61]; inhibits the growth of B16 melanoma
cells [77]; promote apoptosis in leukemia cells [51]; protective role against lung cancer [60]; Decrease plasma glucose
level in blood [59]; Strong activity in inhibition glioma cells
A172 and T98G, breast cancer cells MCF7 and MDAMB-468,
lung cancer cells H838, prostate cancer cells LNCap and
PC3, pancreatic cancer cells HPAC and Panc-1, lung cancer
cells A549 and H358 [78,79].
Largest absorption amount in jejunum and the fastest absorption rate in duodenum in rat experiment [78].
Inhibitory effects on hepatocyte apoptosis and liver ﬁbrosis,
reduce liver damage [84]; anti-inﬂammatory, anti-diabetic,
antioxidant, anti-tumor, antimicrobial and anti-viral properties against ﬂu, hepatitis and HIV [55]; Insulin resistance
and reduce blood glucose level [56]; Anti-SARS-coronavirus
[85], HIV, RSV, and Herpex simplex virus such as it reduces
HMGB1 binding to DNA, and inhibit inﬂuenza virus polymerase activity; settle disturbed digestion; anti-inﬂammatory activity and reduce liver damage in Hepatitis B [54,86
e88]
Oral ingestion, partially digested by intestinal microﬂora
(converts in to 18b-glycyrrhetinic acid) and complete absorption from the gut (18 b-glycyrrhetinic acid is metabolized to 3b-monoglucuronyl-18b-glycyrrhetinic acid in the
liver)

Antioxidant, cytoprotective, vasoprotective, anticarcinogenic, neuroprotective and cardioprotective activities [63];
Virucidal activity against enveloped viruses such
as mengovirus, herpes simplex, para inﬂuenza type
3, pseudorabies, respiratory syncytial, and Sindbis viruses
[94e97]; Targets, some non-structural proteins, including
Nsp3b, Nsp3e, Nsp7_Nsp8 complex, Nsp9, Nsp10, Nsp14,
Nsp15, and Nsp16, thereby affected the SARS-Cov2 virus
RNA synthesis and replication [32].
Absorbed in small intestine and colon and rapidly metabolize in liver and circulate as methyl, glucuronide, and
sulfate metabolites [98,99].

Ginsenoside (Rh2)
A-Panaxadiol
group

Rutin: Quercetin
3-rutinoside

Glycyrrhizic acid

Previous reports

Potential ligands

11e19 h
[100,101]

Generally recognized
as safe, non-lethal with
mild chronic intoxication (mild hypertension, hypokalemia,
edema, rhabdomyolysis or myoglobinuria
[89,90]; Reduction of
blood potassium level,
which affects body
ﬂuid balance and
nerves; increase body
weight, muscle weakness, inhibition
of cortisol metabolism
within the kidney [91
e93]
Safe (Non-toxic) over
dose cause some side
effects including mild
headache, ﬂushing,
rashes, or stomach
upset

No toxic effect [82,83]

16 min. [80,81]

3.5 h (in human)

Toxicity

Half life

Table 1. Half-life, toxicity, sustainability in human system and solubility of identiﬁed ligands.
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(continued on next page)

1:5 solution of
DMF:PBS (pH 7.2)

Water

Very sustainable and
digestible

Oral intake inhibit
platelets aggregation;
poor absorption [102].

DMSO and PBS
buffer

Solubility

Vary in different
reports (as per the
mode of treatment and
concentration)

Sustainability
in Human
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Anti-Inﬂammatory, insecticidal, rodenticidal, Anti-malarial,
antibacterial, hepatoprotective, anti-oxidant, anti-diarrhoeal, deobstruent, diuretic, anti-diabetic, cathartic, emetic,
anti-rheumatic, antihypertensive, anti-fertility, anthelmintic, anti-pyretic and cytotoxic activities [103]; Reduce the
load of Herpes simplex virus I and abolish ocular inﬂammation [104]; Pleiotropic agent that affects the replication of
viral DNA and RNA and modulate the NFkB signaling
pathway [105]; Inhibits HSV1 and HSV 2 replication [106];
Suppress H1N1, H3N2, and B inﬂuenza viruses replication
[107]; Anti-SARS-coronavirus [108].
Immunomodulatory, antioxidative, cardioprotective, hepatoprotective, and renoprotective effects [33,110e112].
Reducing fever, common cold, respiratory infections, and
inﬂuenza [113]; Effective against metabolic diseases [114],
diarrhea [115] and intestinal parasites [116]; repair mucous
membranes of the upper respiratory tract and gastrointestinal system [117,118]; ant-inﬂuenza [119]; anti-Zica virus
[120]; Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling [121]; Inhibit enterovirus-71
replication by modulating MEK/ERK signaling pathway and
autophagy [40]; Suppress the infection of Middle east respiratory syndrome (MERS-CoV) coronavirus [122]; useful
for the prevention and management of novel coronavirus
(SARS-CoV-2) infection [123,124]
Berberine is absorbed in Intestine of human body.
Berberine accumulates within the intestine, where it may be
metabolized by intestinal ﬂora to improve its therapeutic
effect on diabetes [125].
Useful for cardiovascular function, type II diabetes, and
anti-inﬂammation, cutaneous functions, wound healing, UV
protection, anti-inﬂammation, antimicrobial, antiskin cancer, and skin lightning [131]; reduce Rotavirus Infectivity
[132]; anti-proliferative effect on human leukemic K562 cells
[133]; reduce the replication of inﬂuenza virus [134,135];
inhibits enterovirus 71 replication [136]; protease inhibitor
of SARS coronavirus [137]; potential 3CLpro inhibitors in
SARS-CoV-2 [32]
Multiple absorption (in blood stream, different tissues and
intestine) [138,139].

Meliacarpin:
122616-69-7

Hespiridin

Berberine: 208683-1

Previous reports

Potential ligands

Toxicity
Gastrointestinal,
Cardiovascular, Respiratory, or Neurological
Effects, and high dose
can be leads death in
insects but human
poisoning is rarely reported [109].

Non-toxic with least
side effects such as
cramping, diarrhea,
ﬂatulence, constipation
and stomach pain in
the case of high dose
without recommendation [127,128]

Non-toxic

Half life
Not Determine

4e4.5 h [126]

6 h [140]

Ameliorate gut microbiota
and very sustainable [138]

Soluble in
DMSO and
dimethyl
formamide

The salts are soluble in water, stable
in acidic, and
neutral media,
while the base is
soluble in organic
solvents [129,130].

Partial soluble;
Complete soluble
in organic solvents

Not Determine

Very sustainable and useful in drug delivery system also

Solubility

Sustainability
in Human

ORIGINAL ARTICLE

Table 1. (continued )

564
JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:559e580

Under trail drug which possess Inhibitory effect against
SARS-CoV-2 (2019-nCoV) [147e150]; Useful in cardiac disease, including coronary artery disease with anti-gout effect
[67,68]; Effective against Chikungunya, EpsteineBarr and
cytomegalovirus [151,152]; Prevent the inﬂammatory cardiac disorders, including stable coronary artery disease and
postpericarditomy syndrome [153,154] Pericardiotomy
related issues in viral infections [155,156]; Suppress the
infection of Inﬂuenza virus [157]
Directly absorbed in the jejunum and ileum [68].
Use in the treatment of small cell lung cancer, brain tumors,
Hodgkin's lymphoma, neuroblastoma, malignant lymphoma,
reticulocyte sarcoma, acute leukaemia and acute lymphocytic
leukemia which induce apoptosis by acting as topoisomerase
II inhibitors [161,162]; Transcription factor MYB inhibitor
which suppress the infection of avian myeloblastosis virus
[163]; Inhibit the replication of Simian Virus 40 (SV40) [164];
Suppress adenovirus infection [165].

Use for the treatment of genital warts and molluscum
contagiosum during human papiloma virus infections
[167,168]; Supress testicular, breast, pancreatic, lung, stomach, and ovarian cancers [169]; Use as cathartic, purgative,
vesicant, anti-helimenthic and anti-tumor agent [170]; antineoplastic and antiviral activities [171]; inhibit the replication of measles and Herpes simplex type 1 viruses [172,173];
Inhibits the growth of P-388 murine leukemia and A-549
human lung carcinoma [174]

Colchicine: 64-86-8

Podophyllotoxin:
518-28-5

Teniposide: VM26

Effective against testicular cancer, lung cancer, lymphoma,
leukemia, neuroblastoma and ovarian cancer because of
topoisomerase inhibitor activity [62]; Suppress the Epstein
eBarr virus (EBV), HSV-1, Paramyxo viruses and HIV
infection [141e144]; Predicted drug which possess Inhibitory effect against SARS-CoV-2 (2019-nCoV) [145]
Directly absorb in blood stream of human body [62]

Etoposide: 3341942-0

Higher dose causes
Gastrointestinal
toxicity, hypersensitivity reactions and
reversible alopecia
[161]

Minimal side effects,
which are typically
limited to itching,
swelling, irritation,
burning and redness
[176]; embroytoxic effect during pregnancy
[177]; prohibited during breast feeding
[178].

6e8 h [166]

1.0e4.5 h [175]

20-40- hrs [158]

High dose of
Etoposide is relatively
cell cycle speciﬁc, and
it affects cells in the S
and G2 phases of cell
division. Myelo
suppression, mild
thrombocytopenia,
mucositis, nausea, alopecia, and emesis. Low
blood cell counts,
vomiting, loss of appetite, diarrhea, hair loss,
and fever [146]; FDA
reference ID: 2919360)
Non- toxic; Higher
dose may be cause
Diarrhea, nausea,
cramping,
abdominal pain,
and vomiting [148,159]

1.5 h (Half-life
and terminal
elimination
half-life ranging
from 4 to 11 h
(FDA reference
ID: 2919360)

Intravenous
application
burns if it leaks
under the skin; Contraindicated during
pregnancy and lactation,
with severe liver or kidney
impairment or severely
impaired haematopoiesis
[161].
Safe for topical use;
however, it can
cause CNS
depression as well
as enteritis if ingested

Oral administration is
sustainable (but as per the
prescribe
limitation)

Intravenous dose cause
fetal harm during
pregnancy; One of the
World Health Organization's List of Essential
Medicines, the
safest and most effective
medicines for
health system [62].
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(continued on next page)

Soluble in organic
solvents such
as ethanol, DMSO,
and dimethyl formamide (DMF) [179].

Sparingly soluble in
aqueous solution;
1:1
solution
of
DMSO:PBS
(pH
7.2)

Soluble in DMSO
(14 mg/ml), 100%
ethanol (7 mg/ml),
water (7 mg/ml) or
dimethylformamide (12 mg/ml)
[160].

Water soluble
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DMSO, Water,
Methanol
Vary in different reports
(as per the mode of treatment and
concentration)
No toxic effect [191]
Tribulosin: 7997446-2

6e8 Days [194]

Soluble in DMSO
to 100 mM and in
ethanol to 100 mM
[189]
Oral administration [185]
Mostly non-toxic; High
dose leads Less headache,
dizziness,
nausea, and weakness
[180]
Not-Determine
Ampelopsin

Antioxidative, anti-inﬂammatory, anticancer, antimicrobial,
cell death-mediating, and lipid and glucose metabolism
eregulatory activities [180]; use in the treatment of
nephritis, hepatitis, halitosis, and polyorexia [181]; Antiaging and anti-neurodenerative diseases [182,183]; exerts
anti-inﬂammatory effects in fatty liver disease [184]; Protects
against acute brain injury [185]; Induce growth inhibition
and apoptosis in Breast Cancer [186]; Protect against Alzheimer disease, Parkinson's disease, depressive disorder,
hypobaric hypoxia or fetal alcohol exposure (FAE) induced
brain injury and behavioral deﬁcits along with osteoporosis,
asthma, kidney injury, nephrotoxicity [73]; anti-inﬂuenza
and anti hepatitis activity [187,188]; Inhibit replication of
infectious bronchitis virus [115]
Protects myocardium against ischemia/reperfusion injury
through PKC3 activation [190]; Cytoprotective effects in
heart [191]; Maintain the testosterone level; reduce the
cholesterol and triglyceride levels in blood [192].
Multiple absorption (in blood stream, different tissues and
intestine) [193]

Solubility
Sustainability
in Human
Toxicity
Half life
Previous reports
Potential ligands
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greater dG values. In case of main protease, the
binding afﬁnity of selected ligands varied between
366.74 and 1312.5 (induced-ﬁt method), and 6.1
and 9.4 (electrostatic docking). For spike protein, it
ranged from 195.9 to 686.6 when ligands were
analyzed following induced-ﬁt method and 6.3 to
9.3 in electrostatic docking analysis. The ﬁndings of
present investigation suggest that the selected ligands are not only binding effectively with the nonstructural protein (i.e. main protease) but also
attaching with the structural protein i.e. spike protein of SARS-CoV-2 (Table 2; Table 3).
3.4.1. Docking with main protease
The docking with main protease revealed that
Ginsenoside, Glycyrrhizic acid, Hespiridin, Tribulosin and Teniposide showed high binding energy
indicating their highly efﬁcacy (Table 2). Ginsenoside (dG 1312.5), Glycyrrhizic acid (1250.6) and
Teniposide (931.7) exhibited very high dG values
when analyzed using induced-ﬁt method. Glycyrrhizic acid (9.4), Hespiridin (9.1) and Tribulosin
(9.0) had high binding energy when assessed
through electrostatic interaction method. The
selected ligands showed h-bonding with Gln189,
His41, Ser144, Leu141, His164, His246, Leu242,
Gln110, Asp153, Ser158, Pro108 and Thr196 amino
acid residues, which directly or indirectly participate in active site and secondary hotspot formation,
important for proteolytic cleavage activity of protease domain (Fig. 2).
3.4.2. Docking with spike protein
The docking of selected ligands with spike proteins revealed that Glycyrrhizic acid, Ginsenoside,
Tribulosin, Etoposide and Hespiridin showed high
binding energy (Table 3). Glycyrrhizic acid (686.6),
Ginsenoside (686.3) and Tribulosisn (612.7)
exhibited high dG values when analyzed using
induced-ﬁt method. When analyzed using electrostatic interaction method Glycyrrhizic acid (9.3),
Etoposide (8.7), Tribulosin (8.4) and Hespiridin
(8.3) exhibited high binding energy with spike
protein. The binding energy of these ligands also
indicated that they are not only able to bind with
non-structural targeted proteins but also are able to
bind with structural proteins of SARS-CoV-2
(Fig. S1).
3.5. Positional binding afﬁnity of selective ligands
with main protease
The positional binding activity of ligands showed
the selective preference of ‘O’ moiety (oxygen
moiety) for binding against the various active site

Table 2. Binding energy of ligands against Main protease.
Mpro Human

Ligand

Binding energy dG
(HEX) kcal mole1

Binding energy dG
(VINA) kcal mole1

6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7
6lu7

Remdesivir (Control)
Hydroxychloroquine (Control)
Tribulosin
Berberine
Colchicine
Etoposide
Ginsenoside
Glycyrrhizic acid
Hespiridin
Ampelopsin
Meliacarpin
Podophyllotoxin
Rutin
Teniposide

731.38
537.1
841.8
366.74
701.4
837.9
1312.5
1250.6
691.9
476.2
447.88
720.1
744.2
931.7

9.4
5.6
9
6.1
7.1
8.3
8.4
9.4
9.1
7.3
7.7
8.3
8.9
8.7

residues of main protease active site (Fig. 2). In case
of ginsenoside, glycyrrhizic acid and hesperidin, it is
evident that main chain ‘O’ tends towards the
nucleophilic addition with the amino acid atoms
(OC1, OE1, OE2). The preference of atom self-indicate towards more electronegative interaction,
which makes the h-bonding stronger in case of
these 3 ligands (Fig. 2C,D,J). While in the case of
etoposide again the reactive ‘O’ moiety shows
higher interaction afﬁnity for the NE2 of His41, SG
of Cys145, ‘O’ of Phe140 (Fig. 2E). This electronegative reaction pattern is also followed by podophyllotoxin (Fig. 2G). Teniposide, due to its ﬂexible
torsion ﬂexibility involves a number of atoms of
interacting amino acids and forms more strong
bonds. Involvement of ‘N’ and ‘O’ moiety in teniposide makes it stronger nucleophile adductor to
fuse the amino acids of main protease (Fig. 2F).
The preference for different amino acids of main
protease active site also shows the ability of ligands
to recognize suitable amino acid for binding (Fig. 2).

Again, the functional activities of these ligands are
already known for their anti-inﬂammatory and antiviral activity. Considering the mode of action of
SARS-CoV-2, which may develop cytokine storm in
patients, eventually increases the higher inﬂammatory condition in human body, thus making the
immune system more susceptible and weak to
combat the infection and effects of the virus. Our
selected ligands will be highly useful not only due to
their blocking and binding activity against main
protease and spike protein, but also because of their
anti-inﬂammatory potential and supporting ability
of the human body by reducing the cytokine burst.
Another interesting observation was the binding
of rutin, where it binds in a major cavity apart from
the other ligands that showed more afﬁnity towards
a terminal site (Fig. 2H). As rutin is already known
for its antiviral property, it could be a potent lead
against this virus and as an ingredient in designing
the effective formulation. The binding of these
phytochemical leads were demonstrated by H-

Table 3. Binding energy of ligands against spike protein.
Spike protein

Ligand

Binding energy dG
(HEX) kcal mole1

Binding energy dG
(VINA) kcal mole1

6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg
6lzg

Remdesivir (Control)
Hydroxychloroquine (Control)
Tribulosin
Berberine
Colchicine
Etoposide
Ginsenoside
Glycyrrhizic acid
Hespiridin
Ampelopsin
Meliacarpin
Podophyllotoxin
Rutin
Teniposide

621.6
225.9
612.7
195.9
328.7
327.3
686.3
686.6
416.2
291
226.7
279.4
468.4
482.2

7.4
5.8
8.4
6.8
6.3
8.7
7.1
9.3
8.3
6.9
6.9
7.2
7.8
7.6
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Fig. 1. Representation of molecular interaction between main protease of SARS-CoV-2 and phytomolecules based on molecular docking. (A) hbonding and (B)cavity blocking by ligand in surface representation. In ﬁgure, 1 ¼ Remdesivir; 2 ¼ Hydroxychloroquine; 3 ¼ Ginsenoside;
4 ¼ Glycyrrhizic acid; 5 ¼ Etoposide; 6 ¼ Teniposide; 7 ¼ Podophyllotoxin; 8 ¼ Rutin; 9 ¼ Colchicine; 10 ¼ Hespiridin and 11 ¼ Tribulosin.

bonding with major active site residues which suggest that the ligands with more than 1 torsion center
are effectively targeting and binding with the functional cavities of both the proteins (Fig. 2).

4. Discussion
The infection of SARS-CoV-2 and its devastatingly
spread all over the world through Wuhan city,
Hubei province of China since its ﬁrst report
(December, 2019) has recorded a total of 15,18,03,822

conﬁrmed cases of infection and 3,186,538 deaths in
213 countries including India which accounts for
1,95,57,457 infections and 2,15,542 fatalities till May
2nd, 2021 (https://covid19.who.int/). Its genome assembly is 29,881 bp in length (GenBank no.
MN908947) encoding 9860 amino acids [37,38],
shows 79% similarity with SARS coronavirus that
belongs to the genus b-coronavirus [39]. The virus
was therefore, named as severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on the Taxonomy of Viruses.
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Fig. 2. Ligand activity plot of phytomolecules against the main protease active site residue. In ﬁgure, A ¼ Remdesivir; B¼ Hydroxychloroquine;
C ¼ Ginsenoside; D ¼ Glycyrrhizic acid; E ¼ Etoposide; F¼ Teniposide; G ¼ Podophyllotoxin; H ¼ Rutin; I ¼ Colchicine; J ¼ Hespiridin and
K ¼ Tribulosin.

There are so many studies executed for in-depth
knowledge about SARS-CoV-2 to develop effective
drugs. But unfortunately, till date neither any
authentic information nor any speciﬁc drug is
available in the market for cure and prevention of
COVID-19 caused by SARS-CoV-2. However, some
previously used anti-viral drugs (against SARS and
MERS) were screened by investigators, but only
plant based Hydroxychloroquine and synthetic
Remidesvir were reported to suppress the proliferation of SARS-CoV-2 in cell based in-vitro assay [40].
Now, it has been approved by the WHO for global

consumption against SARS-CoV-2 infections as
preventive measures [7]. However, the mode of action of these antiviral drugs against SARS-CoV-2 in
human system has not been reported yet. Further
research is being carried out on various synthetic
molecules e.g. favipiravir, ivermectin, ribavirin etc.
Apart from the synthetic molecules, several herbal
molecules are also being tried for their anti-viral
efﬁcacy. A few such herbal claims with ability to
cure fever, cough, fatigue and related illness hold
promise for effective herbal formulations against
SARS-CoV-2 [41]. However, development of an
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effective herbal drug against SARS-CoV-2 based on
quality screening and scientiﬁc validation is yet to
be a reality. Therefore, the present investigation was
carried out to assess the efﬁcacy and binding afﬁnities of the selected ligands/molecules with functional active sites in main protease (non-structural
protein) and spike protein (structural protein) of
SARS-CoV-2.
Traditional medicines and herbal products from
different medicinal plants have immense potential
to provide leads for therapeutically important
compounds. Due to genetic and environmental diversity, a given medicinal plant species also varies
in their chemical constituents [42,43]. Utilization of
different herbal compounds/molecules as potent
therapeutic agents against several ailments has
gained momentum in recent years globally. Therefore, 40 herbal compounds were selected based on
their previous applications/therapeutic uses for
screening their ability to prevent COVID-19 on the
basis of receptor-ligand docking on main active sites
of SARS-CoV-2. Similar in silico screening of herbal
compounds against SARS-CoV-2 has been undertaken recently by several workers [44e47].
SARS-CoV-2 contains several structural proteins
including S, E, M, and N protein [48] along with
non-structural proteins including papain-like protease, main protease as 3-chymotrypsin-like protease, and RNA-dependent RNA polymerase. Out of
all the structural proteins, spike proteins initiate the
host attachment and fusion of viral membrane
during pathogenicity [32]. The main protease (Mpro)
of previous SARS coronaviruses is the most studied
protein, and also in SARS-CoV-2, it is responsible
for the proteolytic cleavage of pp1a and pp1ab
proteins for the initiation of viral replication and
pathogenicity in the host [49]. Therefore, based on
the structural description and inhibition mechanisms of the previously reported SARS-CoV, Mpro
was made as the target for the suppression of SARSCoV-2 infection [50]. This was the main reason for
the selection of spike like proteins (structural protein) and main protease (non-structural protein) for
the in silico screening of most potent herbal leads
against SARS-CoV-2 [50e52].
The computational docking through Induced ﬁt
method and electrostatic binding, suggests that the
screened herbal molecules/compounds including
Glycyrrhizic acid, Ginsenoside, Tribulosin, Etoposide, Hesperidin and Rutin showed very promising
binding afﬁnity with spike protein. Similarly, a few
compounds such as Ginsenoside, Glycyrrhizic acid,
Teniposide, Tribulosin, Etoposide, Podophyllotoxin,
Rutin, Cochicine and Hesperidin also showed
higher value with main protease in induced ﬁt and

secondary electrostatic screening, which indicates
that selected ligands are not only targeting speciﬁc
amino acids but also are able to block the reported
main active site of the main protease. Many earlier
workers have also shown that phytocompounds
possess signiﬁcant anti-viral activities [17,53]. For
instance, Glycyrrhizic acid derivatives used for
treating chronic hepatitis, not only suppress the
replication of SARS-CoV [54] but also possess antioxidant, anti-inﬂammatory and anti-diabetic properties [55,56]. Ginsenoside derived from Panax
ginseng, inhibits the glycoprotein activity of SARSCoV [57,58]. Since lungs infection and elevated
blood sugar level are directly associated with
COVID-19 infection, Ginsenoside can reduce the
plasma glucose level in blood and could be beneﬁcial in controlling lung infection and cardiotoxicity
[59e61].
Etoposide is a well-known antitumoral compound, also screened as protease (3CLpro) inhibitor
of SARS-CoV-2 [38]. Because of its beneﬁciary role
in reducing infections and enhancing immunity,
WHO has included etoposide in its list of essential
medicines [62]. Similarly, rutin (ﬂavonoid), a wellknown anti-oxidant and antimicrobial agent [63]
was useful for the suppression of Murine CoV [64].
Rutin possibly initiates the suppression of functional protein assembly and host inﬂammation
during the infection of SARS-CoV-2 [65]. It has been
reported that colchicine, an anti-rheumatic drug
efﬁciently suppresses the activation of nucleotide
binding protein and leucine rich repeat protein 3
assemblies, and diminishes the level of cytokine
storm during SARS-CoV-2 infection [66]. It is also
very useful in cardiac disease and signiﬁcantly
possesses antioxidant along with several health
beneﬁcial properties [67,68]. Similarly, Hesperidin
can prevent the host cell entry of the viron through
interaction with ACE2 receptors and thereby suppressing the infection. Additionally, the anti-inﬂammatory and immunity boosting ability of
Hesperidin might provide a better option for controlling cytokine storm in SARS-CoV-2 infection
[69]. This is indicated in the present study with
higher binding afﬁnity of selected herbal compounds with spike protein as well as main protease.
A few compounds viz., Tribulosin, Teniposide (FDA
approved thiol-reacting drug) and Podophyllotoxin
also showed promising binding efﬁciency with main
protease and spike protein which is not yet explored
for their anti-SARS-CoV-2 activities. However, these
phytocompounds have such signiﬁcant broad
spectrum therapeutic applications as anti-oxidants,
immune-stimulants, hormone balancers, and are
used for treating cancer, liver, kidney and

cardiovascular disorders [70e73]. Although, fever,
dry cough, dyspnea, fatigue and myalgia are the
most commonly reported symptoms of COVID-19,
insufﬁcient immune response also leads to severe
damage of cardiovascular system, gut, kidneys and
brain. It enhances blood glucose level manifold in
infected people and also leads to blood clot, vessel
destruction, pulmonary embolism, loss of memory,
and diarrhea. Besides controlling viral infection in
COVID-19 patients, the selected herbal compounds
also possess several other beneﬁciary properties
which reduce the adverse effects of COVID-19.
Although, a comprehensive wet lab validation and
critical clinical trials are required to conﬁrm the
pharmacological activities of these compounds, yet
the in silico study has provided important leads for
the development of most potent herbal drug against
SARS-CoV-2 in near future.

5. Conclusion
In the present investigation, 40 phytomolecules
were analyzed, of which 12 phytomolecules were
found potential, and can block or stabilize the major
functional sites of main protease and spike-RBD
protein. Ginsenoside, Glycyrrhizic acid, Hespiridin
and Tribulosin exhibited high binding energy with
both main protease and spike protein. Etoposide
showed good binding energy only with Spike protein and Teniposide had high binding energy only
with main protease. Our ﬁndings suggest that the
identiﬁed phytomolecules could be promising leads
against the infection of SARS-CoV-2 as the spike
protein is the one that recognizes human ACE-2
receptors and is the known entry point for the virus
into the host cell. The blocking response will reduce
the initial recognition and infection of the virus in
human body, while docking with the main protease
indicates that our leads can play crucial role to
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stopping the proteolytic cleavage done by the main
protease, and could be a deciding step in decreasing
the growth rate in later stage of viral life cycle.
Molecular docking shows that phytomolecules
such as ginsenoside, glycyrrhizic acid and teniposide showed greater binding potential than the
established drugs like Remdesvir and Hydroxychloroquine. Two ligands colchicine and rutin targeted the other hotspots of protein than the
reported active site which makes them as promising
targeted medicine. Phytomolecules such as tribulosin, ginsenoside and podophyllotoxin showed
structural similarity with Remdesivir, which indicates that such structures has higher recognition
for amino acids at the binding site. Apart from
blocking the target proteins of SARS-CoV-2, these
ligands have anti-inﬂammatory and immunomodulating activities thereby lowering the acute
symptoms and fastening the recovery.
The ﬁndings of this study are useful to initiate in
vitro and in vivo experimentation for ﬁnding potential drug molecules for the treatment of SARS-CoV2 infections. In addition, different permutations and
combinations of these phytomolecules may also be
tried to achieve positive synergistic effects with
enhanced bioavailability.
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Appendix A.

Fig. S1. Molecular interaction between spike protein of SARS-CoV-2 and potent phyto-molecules. Representation of molecular interaction
between spike protein of SARS-CoV-2 and phytomolecules based on molecular docking. Figure (A) representing h-bonding and Figure (B) showing the
cavity blocking by ligand in surface representation. In ﬁgure, 1¼Remdesivir; 2¼ Hydroxycloroquine; 3¼ Ginsenoside; 4¼ Glycyrrhizic acid; 5¼
Etoposide; 6¼ Taniposide; 7¼ Podophyllotoxin; 8¼ Rutin; 9¼ Colchicine; 10¼ Hespiridin and 11¼ Tribulosin.
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Fig. S2. Ligand leads with highlighted moieties.
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Table S1. ADMET properties of most potential leads
Parameters

Ampelopsin

Berberine

Colchicine

Etoposide

Ginsenoside

Glycyrrhizic
acid

Ames mutagenesis
Acute Oral Toxicity (c)
Androgen receptor binding
Avian toxicity
Blood Brain Barrier
BRCP inhibitior
Biodegradation
Caco-2
Carcinogenicity (binary)
Crustacea aquatic toxicity
CYP1A2 inhibition
CYP2C19 inhibition
CYP2C9 inhibition
CYP2C9 substrate
CYP2D6 inhibition
CYP2D6 substrate
CYP3A4 inhibition
CYP3A4 substrate
Eye corrosion
Eye irritation
Hepatotoxicity
Human Intestinal Absorption
Human oral bioavailability
Acute Oral Toxicity
P-glycoprotein inhibitior
P-glycoprotein substrate
OATP1B1 inhibitior
OATP1B3 inhibitior
OATP2B1 inhibitior
OCT1 inhibitior
OCT2 inhibitior
P-glycoprotein inhibitior
P-glycoprotein substrate
Plasma protein binding
Subcellular localization
Thyroid receptor binding
Water solubility

e
II
þ
e
e
e
e
e
e
e
þ
e
e
e
e
e
þ
e
e
þ
þ
þ
e
3.246833086
e
e
þ
þ
e
e
e
e
e
1.067124009
Mitochondria
þ
2.99937319

e
III
þ
e
þ
e
e
þ
e
þ
þ
e
e
e
þ
e
e
þ
e
e
þ
þ
e
1.5449361
þ
e
þ
þ
e
þ
e
þ
e
0.8344979
Mitochondria
þ
2.97369

e
III
þ
e
þ
e
e
þ
e
e
e
e
e
e
e
e
e
þ
e
e
þ
þ
þ
2.2246482
e
þ
þ
þ
e
e
e
e
þ
0.4847819
Nucleus
þ
2.560883

e
III
þ
e
e
e
e
e
e
e
e
e
e
e
e
e
e
þ
e
e
e
þ
þ
2.6902423
e
þ
þ
þ
e
e
e
e
þ
0.8784482
Mitochondria
þ
3.507494

e
II
þ
e
e
e
e
e
e
e
e
e
e
e
e
e
e
þ
e
e
e
e
e
3.159646034
þ
e
þ
þ
e
e
e
þ
e
0.985907972
Mitochondria
e
4.333252

e
IV
þ
e
e
e
e
e
e
e
e
e
e
e
e
e
e
þ
e
e
e
þ
e
2.132831097
þ
e
e
e
e
e
þ
þ
e
0.931964338
Mitochondria
e
4.512803577

Hespiridin

Hydroxychloroquine

Meliacarpin

Podophyllotoxin

Remidesvir

Rutin

Taniposide

Tribulosin

e
III
e
e
e
þ
e
e
e
e
e
e
e
e
e
e
e
þ
e
e
þ
þ
e
2.257097
e
e
þ
þ
e
e
e
e
e
1.0964364
Mitochondria
þ
2.648535

þ
III
e
e
þ
e
e
þ
e
þ
e
e
e
e
e
þ
e
þ
e
e
e
þ
þ
2.664962053
e
þ
þ
þ
e
þ
e
e
þ
0.756124914
Lysosomes
þ
3.565742248

þ
I
þ
e
þ
e
e
e
e
þ
e
e
e
e
e
e
e
þ
e
e
e
þ
e
4.12018585
e
þ
þ
þ
e
e
e
e
þ
0.94871801
Mitochondria
þ
3.59128747

e
III
þ
e
þ
e
e
þ
e
e
e
þ
þ
e
e
e
þ
þ
e
e
þ
þ
e
1.972803831
e
e
þ
þ
e
e
e
e
e
0.936204255
Mitochondria
þ
3.47339466

e
III
þ
e
þ
e
e
e
e
þ
e
e
e
e
e
e
e
þ
e
e
þ
þ
e
3.42793131
þ
þ
þ
þ
e
e
e
þ
þ
1.18216193
Lysosomes
þ
3.4735559

e
III
þ
e
e
e
e
e
e
e
e
e
e
e
e
e
e
þ
e
e
þ
þ
e
2.593124
e
e
þ
þ
e
e
e
e
e
0.982454
Mitochondria
þ
2.7724

þ
III
þ
e
þ
e
e
e
e
e
e
þ
e
e
e
e
þ
þ
e
e
þ
þ
e
2.90450954
e
þ
e
e
e
e
e
e
þ
0.96763605
Mitochondria
þ
3.198662

e
II
þ
e
e
e
e
e
e
þ
e
e
e
e
e
e
e
þ
e
e
e
e
e
4.589214
þ
e
þ
þ
e
e
þ
þ
e
0.725269
Mitochondria
e
3.4138

References
[1] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al.
A pneumonia outbreak associated with a new coronavirus
of probable bat origin. Nature 2020;579(7798):270e3.
[2] De Wit E, Van Doremalen N, Falzarano D, Munster VJ.
SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14(8):523.
[3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early
transmission dynamics in Wuhan, China, of novel
coronaviruseinfected pneumonia. New Engl J Med 2020;
382(13):1199e207.
[4] Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antiviral Chem
Chemother 2018;26. 2040206618764483.
[5] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J,
Bruce H, et al. First case of 2019 novel coronavirus in the
United States. New Engl J Med 2020.
[6] Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine
prophylaxis for COVID-19 contacts in India. Lancet Infect
Dis 2020;20(10):1118e9.
[7] World Health Organization. Informal consultation on the
potential role of chloroquine in the clinical management of
COVID 19 infection. Geneva, Switzerland. 13th March 2020.

[8] Bhinde S. Rasayana: a better alternative for disease prevention. J Ayurveda Holistic Med 2013;1:6e14.
[9] Acharya YT, Samhita Charaka, editors. Varanasi: Chowkhamba Surbharati; 2000 (Ch. Vi. 3/6).
[10] Samal J. Fundamental tenets of epidemiology in Ayurveda
and their contemporary relevance. IJHMS 2016;9(1):20.
[11] Basak A, Cooper S, Roberge AG, Banik UK, Chretien M,
Seidah NG. Inhibition of proprotein convertases-1,-7 and
furin by diterpines of Andrographis paniculata and their
succinoyl esters. Biochem J 1999;338:107e13.
[12] Majumdar S, Mohanta BC, Chowdhury DR, Banik R,
Dinda B, Basak A. Proprotein convertase inhibitory activities of ﬂavonoids isolated from Oroxylum indicum. Curr
Med Chem 2010;17(19):2049e58.
[13] Pel P, Chae HS, Nhoek P, Kim YM, Chin YW. Chemical
constituents with proprotein convertase subtilisin/kexin
type 9 mRNA expression inhibitory activity from dried
immature Morus alba fruits. J Agr Food Chem 2017;65(26):
5316e21.
[14] Muthuramalingam P, Jeyasri R, Valliammai A, Selvaraj A,
Karthika C, Gowrishankar S, et al. Global multi-omics and
systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules
against COVID-19: An in silico approach Genomics 2020;
112(6):4486e504.

ORIGINAL ARTICLE

575

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:559e580

576

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:559e580

ORIGINAL ARTICLE

[15] Mehany T, Khalifa I, Barakat H, Althwab SA, Alharbi YM,
El-Sohaimy S. Polyphenols as promising biologically active
substances for preventing SARS-CoV-2: a review with
research evidence and underlying mechanisms. Food Biosci
2021:100891.
[16] Khalifa I, Nawaz A, Sobhy R, Althwab SA, Barakat H. Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CLpro of 2019-nCoV than
monomeric anthocyanins: a structural-relationship activity
study with 10 anthocyanins using in-silico approaches.
J Mol Graph Model 2020;100:107690.
[17] Khalifa I, Zhu W, Mohammed HH, Dutta K, Li C. Tannins
inhibit SARS-CoV-2 through binding with catalytic dyad
residues of 3CLpro: an in silico approach with 19 structural
different hydrolysable tannins. J Food Biochem 2020;44(10):
e13432.
[18] Hassan ST, Masarcíkov
a R, Berchov
a K. Bioactive natural
products with anti-herpes simplex virus properties. J Pharm
Pharmaco 2015;67(10):1325e36.
[19] Mukherjee H, Ojha D, Bag P, Chandel HS, Bhattacharyya S,
Chatterjee TK, et al. Anti-herpes virus activities of Achyranthes aspera: an Indian ethnomedicine, and its triterpene
acid. Microbiol Res 2013;168(4):238e44.
[20] Cheng HY, Yang CM, Lin TC, Lin LT, Chiang LC, Lin CC.
Excoecarianin, isolated from Phyllanthus urinaria Linnea,
inhibits herpes simplex virus type 2 infection through
inactivation of viral particles. Evid-Based Complementary
Altern Med 2011;2011:259103.
[21] Gescher K, Kühn J, Hafezi W, Louis A, Derksen A, Deters A,
et al. Inhibition of viral adsorption and penetration by an
aqueous extract from Rhododendron ferrugineum L. as antiviral principle against herpes simplex virus type-1. Fitoterapia 2011;82(3):408e13.
[22] Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a
review of virusehost interactions. Diseases 2016;4(3):26.
[23] Bertol JW, Rigotto C, de P
adua RM, Kreis W, Barardi CRM,
Braga FC, et al. Antiherpes activity of glucoevatromonoside,
a cardenolide isolated from a Brazilian cultivar of Digitalis
lanata. Antiviral Res 2011;92:73e80.
[24] Ikeda K, Tsujimoto K, Uozaki M, Nishide M, Suzuki Y,
Koyama AH, et al. Inhibition of multiplication of herpes
simplex virus by caffeic acid. Int J Mol Med 2011;28(4):595e8.
[25] Yarmolinsky L, Zaccai M, Ben-Shabat S, Mills D,
Huleihel M. Antiviral activity of ethanol extracts of Ficus
Binjamina and Lilium candidum in vitro. N Biotechnol 2009;
26(6):307e13.
[26] Chin LW, Cheng YW, Lin SS, Lai YY, Lin LY, Chou MY,
et al. Anti-herpes simplex virus effects of berberine from
Coptidis rhizoma, a major component of a Chinese
herbal medicine, Ching-Wei-San. Arch Virol 2010;155(12):
1933e41.
[27] Bag P, Ojha D, Mukherjee H, Halder UC, Mondal S,
Biswas A, et al. A dihydro-pyrido-indole potently inhibits
HSV-1 infection by interfering the viral immediate early
transcriptional events. Antiviral Res 2014;105:126e34.
[28] Bag P, Ojha D, Mukherjee H, Halder UC, Mondal S,
Chandra NS, et al. An indole alkaloid from a tribal folklore
inhibits immediate early event in HSV-2 infected cells with
therapeutic efﬁcacy in vaginally infected mice. PLoS One
2013;8:77937.
[29] Khanal P, Duyu T, Dey YN, Patil BM, Pasha I, Wanjari M.
Network pharmacology of AYUSH recommended immuneboosting medicinal plants against COVID-19. 2020.
[30] Trinchieri G. Interleukin-12 and the regulation of innate
resistance and adaptive immunity. Nat Rev Immunol 2003;
3(2):133e46.
[31] D'Alessandro S, Scaccabarozzi D, Signorini L, Perego F,
Ilboudo DP, Ferrante P, et al. The use of antimalarial drugs
against viral infection. Microorganisms 2020;8(1):85.
[32] Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al.
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta
Pharm Sin B 2020;10(5):766e88.

[33] Liu X, Wang XJ. Potential inhibitors against 2019-nCoV
coronavirus M protease from clinically approved medicines. J Gent Genomics 2020;47(2):119.
[34] Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a
program to generate schematic diagrams of protein-ligand
interactions. Protein Eng Des Sel 1995;8(2):127e34.
[35] Gil C, Ginex T, Maestro I, Nozal V, Barrado-Gil L, CuestaGeijo MA, et al. COVID-19: drug targets and potential
treatments. J Med Chem 2020;63(21):12359e86.
[36] Narkhede RR, Pise AV, Cheke RS, Shinde SD. Recognition
of natural products as potential inhibitors of COVID-19
main protease (Mpro): in-silico evidences. Nat Prod Bioprospect 2020;10(5):297e306.
[37] Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al.
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical
pneumonia after visiting Wuhan. Emerg Microbes Infect
2020;9:221e36.
[38] Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA
based mNGS approach identiﬁes a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan
outbreak. Emerg Microbes Infect 2020;9:313e9.
[39] Lu Q, Shi Y. Coronavirus disease (COVID-19) and neonate:
what neonatologist need to know. J Med Virol 2020;92(6):
564e7.
[40] Wang H, Li K, Ma L, Wu S, Hu J, Yan H, et al. Berberine
inhibits enterovirus 71 replication by downregulating the
MEK/ERK signaling pathway and autophagy. Virol J 2017;
14(1):2.
[41] Prasad A, Muthamilarasan M, Prasad M. Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules.
Plant cell rep 2020;39(9):1109e14.
[42] Misra A, Mishra P, Kumar B, Shukla PK, Kumar M,
Singh SP, et al. Intra-speciﬁc molecular and chemical variabilities in natural populations of Gloriosa superba (L.,) for
identifying elite chemotypes for commercial utilization.
Fitoterapia 2021;150:104831.
[43] Misra A, Srivastava S, Kumar S, Shukla PK, Kumar M,
Agrawal PK, et al. Chemotaxonomic studies on natural
population of Gloriosa superba (L.) collected from Gangetic
plain (India) and their in vitro antigout activity for the
identiﬁcation of elite germplasm(s). J Ethnopharmacol 2020;
249:112387.
[44] Kar P, Sharma NR, Singh B, Sen A, Roy A. Natural compounds from Clerodendrum spp. as possible therapeutic
candidates against SARS-CoV-2: an in-silico investigation.
J Biomol Struct Dyn 2020;18:1e2.
[45] Naik B, Gupta N, Ojha R, Singh S, Prajapati VK, Prusty D.
High throughput virtual screening reveals SARS-CoV-2
multi-target binding natural compounds to lead instant
therapy for COVID-19 treatment. Int J Biol Macromol 2020;
160:1e17.
[46] Shawky E, Nada AA, Ibrahim RS. Potential role of medicinal plants and their constituents in the mitigation of SARSCoV-2: identifying related therapeutic targets using
network pharmacology and molecular docking analyses.
RSC Adv 2020;10(47):27961e83.
[47] Zhang DH, Wu KL, Zhang X, Deng SQ, Peng B. In silico
screening of Chinese herbal medicines with the potential to
directly inhibit 2019 novel coronavirus. J Integr Med 2020;
18(2):152e8.
[48] Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The
coronavirus spike protein is a class I virus fusion protein:
structural and functional characterization of the fusion core
complex. J Virol 2003;77:8801e11.
[49] Du QS, Wang SQ, Zhu Y, Wei DQ, Guo H, Sirois S, et al.
Polyprotein cleavage mechanism of SARS CoV Mpro and
chemical modiﬁcation of the octapeptide. Peptides 2004;
25(11):1857e64.
[50] Ullrich S, Nitsche C. The SARS-CoV-2 main protease as
drug target. Bioorg Med Chem Lett 2020;30(17):127377.
[51] Huang J, Peng K, Wang L, Wen B, Zhou L, Luo T, et al.
Ginsenoside Rh2 inhibits proliferation and induces

[52]

[53]

[54]

[55]
[56]

[57]

[58]

[59]

[60]

[61]

[62]
[63]
[64]

[65]

[66]

[67]
[68]
[69]
[70]

apoptosis in human leukemia cells via TNF-a signaling
pathway. Acta Biochim Biophys Sin 2016;48(8):750e5.
Joshi RS, Jagdale SS, Bansode SB, Shankar SS, Tellis MB,
Pandya VK, et al. Discovery of potential multi-targetdirected ligands by targeting host-speciﬁc SARS-CoV-2
structurally conserved main protease. J Biomol Struct Dyn
2020;5:1e6.
Islam MT, Sarkar C, El Kersh DM, Jamaddar S, Uddin SJ,
Shilpi JA, et al. Natural products and their derivatives
against coronavirus: a review of the non-clinical and preclinical data. Phytoth Res 2020:1e22.
Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H,
Doerr HW. Glycyrrhizin, an active component of liquorice
roots, and replication of SARS-associated coronavirus. The
Lancet 2003;361(9374):2045e6.
Ming LJ, Yin AC. Therapeutic effects of glycyrrhizic acid.
Nat Pro Commun 2013;8(3). 1934578X1300800335.
Chia YY, Ton SH, Khalid BAK. Effects of glycyrrhizic acid
on peroxime proliferator-activated receptor gamma (PPARg), lipoprotein lipase (LPL), serum lipid and HOMA-IR in
rats. PPAR Res 2009;6:125e41.
Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, et al.
Identiﬁcation of natural compounds with antiviral activities
against SARS-associated coronavirus. Antivir Res 2005;
67(1):18e23.
Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YS. Small
molecules targeting severe acute respiratory syndrome
human coronavirus. Proc Natl Acad Sci U S A 2004;101:
10012e7.
Lee WK, Kao ST, Liu IM, Cheng JT. Ginsenoside Rh2 is one
of the active principles of Panax ginseng root to improve
insulin sensitivity in fructose-rich chow-fed rats. Hor Metab
Res 2007;39(5):347e54.
Mathiyalagan R, Wang C, Kim YJ, Castro-Aceituno V,
Ahn S, Subramaniyam S, et al. Preparation of polyethylene
glycol-ginsenoside Rh1 and Rh2 conjugates and their efﬁcacy against lung cancer and inﬂammation. Molecules 2019;
24(23):4367.
Wang H, Yu P, Gou H, Zhang J, Zhu M, Wang ZH, et al.
Cardioprotective effects of 20 (S)-ginsenoside Rh2 against
doxorubicin-induced cardiotoxicity in vitro and in vivo.
Evid Based Complementary Altern Med 2012:506214.
World Health Organization. World Health Organization
model list of essential medicines: 21st list 2019 (No. WHO/
MVP/EMP/IAU/2019.06).
Ganeshpurkar A, Saluja AK. The pharmacological potential
of rutin. Saudi Pharm J Saudi 2017;25(2):149e64.
Chiow KH, Phoon MC, Putti T, Tan BK, Chow VT. Evaluation of antiviral activities of Houttuynia cordata Thunb.
extract, quercetin, quercetrin and cinanserin on murine
coronavirus and dengue virus infection. Asian Pac J Trop
Med 2016;9(1):1e7.
Hu X, Cai X, Song X, Li C, Zhao J, Luo W, et al. Possible
SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like
receptor. Future Virol 2020.
Perricone C, Triggianese P, Bartoloni E, Cafaro G,
Bonifacio AF, Bursi R, et al. The anti-viral facet of antirheumatic drugs: lessons from COVID-19. J Autoimmun
2020:102468.
Martinon F, P
etrilli V, Mayor A, Tardivel A, Tschopp J.
Gout-associated uric acid crystals activate the NALP3
inﬂammasome. Nature 2006;440(7081):237e41.
Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology 2018;57(suppl_1):
i4e11.
Haggag YA, El-Ashmawy NE, Okasha KM. Is hesperidin
essential for prophylaxis and treatment of COVID-19
Infection? Me Hypotheses; 2020. p. 109957.
Semerdjieva IB, Zheljazkov VD. Chemical constituents,
biological properties, and uses of Tribulus terrestris: a review.
Nat Prod Commun 2019;14(8):1934578X19868394.

577

[71] Kostova I, Dinchev D. Saponins in Tribulus terrestrisechemistry and bioactivity. Phytochem Rev 2005;4(2e3):
111e37.
[72] He X, Xiang N, Zhang J, Zhou J, Fu Y, Gong T, et al.
Encapsulation of teniposide into albumin nanoparticles
with greatly lowered toxicity and enhanced antitumor activity. Int J Pharm 2015;487(1e2):250e9.
[73] Zhang J, Chen Y, Luo H, Sun L, Xu M, Yu J, et al. Recent
update on the pharmacological effects and mechanisms of
dihydromyricetin. Front Pharmacol 2018;9:1204.
[74] Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS. Effects of
ginsenosides Rg3 and Rh2 on the proliferation of prostate
cancer cells. Arch Pharma Res 2004;27(4):429.
[75] Shi J, Cao B, Zha WB, Wu XL, Liu LS, Xiao WJ, et al.
Pharmacokinetic interactions between 20 (S)-ginsenoside
Rh2 and the HIV protease inhibitor ritonavir in vitro and in
vivo. Acta Pharmacol Sin 2013;34(10):1349.
[76] Kang S, Im K, Kim G, Min H. Antiviral activity of 20 (R)ginsenoside Rh2 against murine gammaherpesvirus.
J Ginseng Res 2017;41(4):496e502.
[77] Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, et al.
Inhibitory effects of ginsenoside Rh2 on tumor growth in
nude mice bearing human ovarian cancer cells. Jpn J Cancer Res 1998;89(7):733e40.
[78] Cao M, Zhang J, Zhao Y, Song X, Ma B. Advances in ginsenoside Rh2 and its derivatives. World Sci Technol 2012;14:
2205e11.
[79] Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R.
In vitro anti-cancer activity and structureeactivity relationships of natural products isolated from fruits of Panax
ginseng. Cancer Chemother Pharmacol 2007;59(5):589e601.
[80] Qian T, Cai Z. Biotransformation of ginsenosides Rb1,
Rg3 and Rh2 in rat gastrointestinal tracts. Chi Med 2010;
5(1):19.
[81] Qian T, Cai Z, Wong RN, Jiang ZH. Liquid chromatography/mass spectrometric analysis of rat samples for in vivo
metabolism and pharmacokinetic studies of ginsenoside
Rh2. Rapid Commun Mass Spectr: Int J Dev Rapid Disseminat Res Mass Spectro 2005;19(23):3549e54.
[82] Carabin IG, Burdock GA, Chatzidakis C. Safety assessment
of Panax ginseng. Int J Toxicol 2000;19:293e301.
[83] Park SJ, Lim KH, Noh JH, Jeong EJ, Kim YS, Han BC, et al.
Subacute oral toxicity study of Korean red ginseng extract
in Sprague-Dawley rats. Toxicol Res 2013;29(4):285e92.
[84] Li JY, Cao HY, Liu P, Cheng GH, Sun MY. Glycyrrhizic acid
in the treatment of liver diseases: literature review. BioMed
Res Int 2014;2014.
[85] Hoever G, Baltina L, Michaelis M, Kondratenko R,
Baltina L, Tolstikov GA, et al. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J Med
Chem 2005;48:1256e9.
[86] Fukuchi K, Okudaira N, Adachi K, Odai-Ide R, Watanabe S,
Ohno H, et al. Antiviral and antitumor activity of licorice
root extracts. In Vivo 2016;30(6):777e85.
[87] Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and
antimicrobial activities of licorice, a widely-used Chinese
herb. Acta Pharm Sin B 2015;5(4):310e5.
[88] Yeh CF, Wang KC, Chiang LC, Shieh DE, Yen MH, San
Chang J. Water extract of licorice had anti-viral activity
against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol 2018;148(2):466e73.
[89] Van Gelderen CE, Bijlsma JA, Van Dokkum W,
Savelkoull TJ. Glycyrrhizic acid: the assessment of a no effect level. Hum Exp Toxicol 2000;19(8):434e9.
[90] Johns C. Glycyrrhizic acid toxicity caused by consumption
of licorice candy cigars. Can J Emer Med 2009;11(1):94e6.
[91] Black licorice: trick or treat? US Food and Drug Administration 30 October 2017. https://www.fda.gov/consumers/
consumer-updates/black-licorice-trick-or-treat.
[92] Ferrari P, Sansonnens A, Dick B, Frey FJ. In vivo 11b-HSD-2
activity: variability, salt-sensitivity, and effect of licorice.
Hypertension 2001;38(6):1330e6.

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:559e580

578

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:559e580

ORIGINAL ARTICLE

[93] Penninkilampi R, Eslick EM, Eslick GD. The association
between consistent licorice ingestion, hypertension and
hypokalaemia: a systematic review and meta-analysis.
J Hum Hypertens 2017;31(11):699e707.
[94] Choi HJ, Kim JH, Lee CH, Ahn YJ, Song JH, Baek SH, et al.
Antiviral activity of quercetin 7-rhamnoside against porcine
epidemic diarrhea virus. Antivir Res 2009;81(1):77e81.
[95] Kaul TN, Middleton Jr E, Ogra PL. Antiviral effect of ﬂavonoids on human viruses. J Med Virol 1985;15(1):71e9.
[96] Vlietinck AJ, Vanden Berghe DA, Haemers A. Present status
and prospects of ﬂavonoids as anti-viral agents. Prog Clin
Biol Res 1988;280:283e99.
[97] Vrijsen R, Everaert L, Boeye A. Antiviral activity of ﬂavones
and potentiation by ascorbate. J Gen Virol 1988;69(7):
1749e51.
[98] Dabeek WM, Marra MV. Dietary quercetin and kaempferol:
bioavailability and potential cardiovascular-related bioactivity in humans. Nutrients 2019;11(10):2288.
[99] Hollman PC. Absorption, bioavailability, and metabolism of
ﬂavonoids. Pharm Biol 2004;42(sup1):74e83.
[100] Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B,
Drewelow B, et al. Pharmacokinetics and bioavailability of
quercetin glycosides in humans. J Clin Pharm 2001;41(5):
492e9.
[101] Olthof MR, Hollman PC, Vree TB, Katan MB. Bioavailabilities of quercetin-3-glucoside and quercetin-40 glucoside do not differ in humans. J Nutr 2000;130(5):
1200e3.
[102] Flavonoids. Micronutrient information center. Corvallis,
Oregon: Linus Pauling Institute, Oregon State University;
November 2015.
[103] Sultana S, Asif HM, Akhtar N, Waqas M, Rehman SU.
Comprehensive review on ethanobotanical uses, phytochemistry and pharmacological properties of Melia azedarach linn. AJPRHC 2014;6(1).
[104] Alche LE, Ferek GA, Meo M, Coto CE, Maier MS. An
antiviral meliacarpin from leaves of Melia azedarach L.
Zeitschrift für Naturforschung C 2003;58:215e9.
[105] Barquero AA, Michelini FM, Alche LE. 1-Cinnamoyl-3, 11dihydroxymeliacarpin is a natural bioactive compound with
antiviral and nuclear factor-kB modulating properties.
Biochem Biophys Res Commun 2006;344:955e62.
[106] Petrera E, Coto CE. The synergistic effect of IFN-a and IFNg against HSV-2 replication in Vero cells is not interfered by
the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin.
Virol J 2006;3(1):45.
[107] Nerome K, Shimizu K, Zukeran S, Igarashi Y, Kuroda K,
Sugita S, et al. Functional growth inhibition of inﬂuenza A
and B viruses by liquid and powder components of leaves
from the subtropical plant Melia azedarach L. Arch Virol
2018;163(8):2099e109.
[108] Kim HY, Shin HS, Park H, Kim YC, Yun YG, Park S, et al. In
vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma,
Meliae cortex, Coptidis rhizoma, and Phellodendron cortex.
J Clin Virol 2008;41(2):122e8.
[109] Phua DH, Tsai WJ, Ger J, Deng JF, Yang CC. Human Melia
azedarach poisoning. Clin Toxicol 2008;46(10):1067e70.
[110] Dai P, Wang J, Lin L, Zhang Y, Wang Z. Renoprotective
effects of berberine as adjuvant therapy for hypertensive
patients with type 2 diabetes mellitus: evaluation via
biochemical markers and color Doppler ultrasonography.
Exp Ther Med 2015;10(3):869e76.
[111] Domitrovic R, Jakovac H, Blagojevic G. Hepatoprotective
activity of berberine is mediated by inhibition of TNF-a,
COX-2, and iNOS expression in CCl4-intoxicated mice.
Toxicol 2011;280(1e2):33e43.
[112] Neag MA, Mocan A, Echeverría J, Pop RM, Bocsan CI,
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